Evidence map›Paper›PMID 26341109›Full record

ArticleClinical endocrinology2016

Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome.

Byambaa Enkhmaa, Erdembileg Anuurad, Wei Zhang, Adnan Abbuthalha, Parneet Kaur, Jasmeen Visla, Sidika Karakas, Lars Berglund

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Management of Dyslipidemia in Endocrine Diseases.Endocrinology and metabolism clinics of North America · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Byambaa EnkhmaaDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
Erdembileg AnuuradDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
Wei ZhangDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
Adnan AbbuthalhaDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
Parneet KaurDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
Jasmeen VislaDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
Sidika KarakasDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
Lars BerglundDepartment of Internal Medicine, School of Medicine, University of California, Davis, CA, USA.
University of California, Davis · USVA Northern California Health Care System · US

Funding

UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
Building Interdisciplinary Research Careers in Womens Health at UC Davis - Administrative SupplementK12HD051958 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI LANE, NANCY E · 2005 to 2023
$9.6M
Regulation of Lipoprotein(a) Metabolism in Humans with Reference to EthnicityR01HL062705 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI BERGLUND, LARS F · 2000 to 2011
$2.9M
Walnuts vs. Walnut-Oil, Glucose Homeostasis, PCOSR21AT002280 · NCCIH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KARAKAS, SIDIKA E · 2006 to 2007
$449k
NCATS NIH HHS UL1 TR000002NCCIH NIH HHS R21 AT002280NHLBI NIH HHS R01 HL062705NICHD NIH HHS K12 HD051958
6 · The paper itself

Abstract

objectiveLevels of lipoprotein(a), Lp(a), an independent risk factor for cardiovascular disease (CVD), are affected by sex hormones. Women with polycystic ovary syndrome (PCOS) have elevated androgen levels and are at increased CVD risk. We investigated the impact of PCOS-related hormonal imbalance on Lp(a) levels in relation to apo(a) gene size polymorphism, a major regulator of Lp(a) level.

designCross-sectional. PATIENTS: Forty-one Caucasian women with PCOS based on the NIH criteria. MEASUREMENTS: (1) Apo(a) gene size polymorphism measured as Kringle (K) 4 repeat number; (2) total plasma Lp(a) level; (3) allele-specific apo(a) level assessing the amount of Lp(a) carried by an individual apo(a) allele/isoform; and (4) sex hormone levels.

resultsThe mean age was 32 ± 6 years, and the mean BMI was 35 ± 8 with 66% of women classified as obese (BMI >30 kg/m

conclusionsThe apo(a) genetic variability remains the major regulator of plasma Lp(a) levels in women with PCOS.

Identifiers

PMID26341109
PMCPMC4779071
OpenAlexW2168217769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.